Larimar Therapeutics (LRMR) Competitors

Larimar Therapeutics (NASDAQ:LRMR) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, community ranking, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Do insiders & institutionals have more ownership in LRMR or PRTA?

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by insiders. Comparatively, 9.2% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the media prefer LRMR or PRTA?

In the previous week, Larimar Therapeutics had 2 more articles in the media than Prothena. MarketBeat recorded 7 mentions for Larimar Therapeutics and 5 mentions for Prothena. Larimar Therapeutics' average media sentiment score of 0.67 beat Prothena's score of 0.43 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prothena	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk and volatility, LRMR or PRTA?

Larimar Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Prothena has a beta of 0.07, meaning that its share price is 93% less volatile than the S&P 500.

Do analysts rate LRMR or PRTA?

Larimar Therapeutics presently has a consensus target price of $19.63, indicating a potential upside of 628.20%. Prothena has a consensus target price of $55.00, indicating a potential upside of 533.64%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Larimar Therapeutics is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.10
Prothena	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Is LRMR or PRTA more profitable?

Larimar Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -90.50%. Prothena's return on equity of -22.67% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-35.87%	-32.37%
Prothena	-90.50%	-22.67%	-19.68%

Which has preferable earnings & valuation, LRMR or PRTA?

Larimar Therapeutics has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$36.95M	-$1.30	-2.07
Prothena	$135.16M	3.46	-$147.03M	-$2.30	-3.77

Does the MarketBeat Community believe in LRMR or PRTA?

Prothena received 566 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. However, 71.88% of users gave Larimar Therapeutics an outperform vote while only 70.43% of users gave Prothena an outperform vote.

Company	Underperform	Outperform
Larimar Therapeutics	Outperform Votes 46 71.88%	Underperform Votes 18 28.13%
Prothena	Outperform Votes 612 70.43%	Underperform Votes 257 29.57%

Summary

Larimar Therapeutics beats Prothena on 12 of the 18 factors compared between the two stocks.